FibroGen announces presentation of FG-4592 Phase 2 data on anemia at ASN Kidney Week 2012

FibroGen, Inc., today announced that two abstracts relating to FG-4592, its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) clinical candidate for the treatment of anemia in chronic kidney disease, have been accepted for oral and poster presentations at the American Society of Nephrology (ASN) Kidney Week 2012. The annual meeting will be held October 30 - November 4, 2012, in San Diego, California. Full abstracts can be viewed online at

The schedule and details for the FG-4592 oral and poster presentations at ASN are as follows:

  • FG-4592, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, Corrects Anemia Without Iron Supplementation in Incident Dialysis Patients.
    Thursday, November 1, 2012, 4:30 p.m. - 6:30 p.m.
    Oral Program # TH-OR096 (Besarab, et al).
  • FG-4592, a Novel Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), Maintains Hemoglobin Levels and Lowers Cholesterol in Hemodialysis (HD) Patients: Phase 2 Comparison with Epoetin Alfa.
    Friday, November 2, 2012, 10:00 a.m. - 12:00 p.m.
    Poster Board # FR-PO257 (Provenzano, et al).

FibroGen, Inc.


  1. Ann Pederson Ann Pederson United States says:

    Please let me know if FG4592 HIF-PHI or OHIFPHI is being used yet. My husband is ESRD and always anemic. Thank you.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Better analysis of kidney tumor samples